Ana Velázquez Mañana, Assistant Professor of Medicine at the University of California, San Francisco, shared a post on LinkedIn:
“The ASCO26 abstract titles are finally out!
This year’s Plenary Session will feature TWO lung cancer phase 3 trials:
- Primary results of LIBRETTO-432: adjuvant selpercatinib in RET+ NSCLC. Presented by Dr. Jonathan Goldman with discussion by Christine M. Lovly
- Overall survival of HARMONi-6: Ivonescimab + chemo vs. Tislelizumab + chemo in squamous NSCLC. Presented by Prof. Shun Lu from Shanghai Chest Hospital with discussion by Dr. Julie Brahmer.“
FDA Accepts BLA for Ivonescimab Plus Chemotherapy in EGFR-Mutated NSCLC After TKI Therapy
